MedTrace Logo

Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors

NCT00407537 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1531

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.

Conditions

Interventions

DRUG

Amlodipine besylate/atorvastatin calcium single pill combination

Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Costa Rica
  • Croatia
  • Czechia
  • Dominican Republic
  • Indonesia
  • Jordan
  • Kuwait
  • Lebanon
  • Malaysia
  • Mexico
  • Panama
  • Philippines
  • Russia
  • Saudi Arabia
  • South Korea
  • Taiwan
  • Thailand
  • Turkey (Türkiye)
  • United Arab Emirates
  • Venezuela

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407537 on ClinicalTrials.gov